Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Buy” by Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned a consensus rating of “Buy” from the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $67.70.

A number of brokerages recently issued reports on JANX. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a research report on Thursday, November 7th. UBS Group began coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target on the stock. Stifel Nicolaus initiated coverage on Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 price target on the stock. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday. Finally, Leerink Partners initiated coverage on Janux Therapeutics in a research note on Friday. They set an “outperform” rating and a $79.00 target price for the company.

Insider Activity

In related news, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the completion of the transaction, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at $15,101,171.16. This trade represents a 8.14 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the transaction, the insider now directly owns 3,162,851 shares of the company’s stock, valued at approximately $132,839,742. This represents a 3.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 420,610 shares of company stock worth $19,288,666. Insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Plato Investment Management Ltd raised its position in Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after purchasing an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after acquiring an additional 339 shares during the period. Amalgamated Bank grew its holdings in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after acquiring an additional 368 shares during the period. Summit Securities Group LLC acquired a new stake in Janux Therapeutics during the 2nd quarter worth about $29,000. Finally, Virtu Financial LLC grew its holdings in Janux Therapeutics by 48.0% during the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after acquiring an additional 2,419 shares during the period. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Trading Down 3.0 %

Janux Therapeutics stock opened at $48.82 on Tuesday. Janux Therapeutics has a 12 month low of $7.79 and a 12 month high of $65.60. The stock’s 50 day moving average is $50.05 and its 200-day moving average is $45.83. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of -41.73 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm’s revenue for the quarter was down 82.6% compared to the same quarter last year. As a group, equities research analysts predict that Janux Therapeutics will post -1.34 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.